Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENSC Ensysce Biosciences	$2.08 +1.0%	$2.15	$1.62 ▼ $14.67	$6.17M	1	807,437 shs	50,654 shs
GLUC Glucose Health	$0.09	$0.10	$0.08 ▼ $0.28	$1.58M	1.79	4,598 shs	1,265 shs
LIAN LianBio	$0.05 +0.4%	$0.20	$0.27 ▼ $4.99	$5.51M	0.23	1.04 million shs	134,127 shs
NBY NovaBay Pharmaceuticals	$1.55 +72.4%	$0.66	$0.44 ▼ $1.90	$9.03M	0.4	2.30 million shs	140.96 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENSC Ensysce Biosciences	+0.49%	+1.48%	-8.04%	-8.85%	-68.66%
GLUC Glucose Health	0.00%	-1.09%	-6.67%	+0.44%	-58.84%
LIAN LianBio	-10.88%	-10.88%	-10.88%	-85.89%	-84.74%
NBY NovaBay Pharmaceuticals	-0.83%	+49.83%	+33.70%	+59.82%	+73.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENSC Ensysce Biosciences	0.3515 of 5 stars	0.0	4.0	0.0	0.0	2.1	0.0	0.0
GLUC Glucose Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	0.7298 of 5 stars	1.5	0.0	0.0	0.0	3.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENSC Ensysce Biosciences	0.00	N/A	N/A	N/A
GLUC Glucose Health	0.00	N/A	N/A	N/A
LIAN LianBio	0.00	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-45.16% Downside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENSC Ensysce Biosciences	N/A	N/A	N/A	N/A	$1.03 per share	N/A
GLUC Glucose Health	$380K	4.17	N/A	N/A	N/A	∞
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
NBY NovaBay Pharmaceuticals	$9.78M	0.92	N/A	N/A	$4.25 per share	0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENSC Ensysce Biosciences	-$7.99M	-$4.03	N/A	N/A	N/A	-88.76%	-167.23%	-104.59%	11/11/2025 (Estimated)
GLUC Glucose Health	-$320K	-$0.03	N/A	∞	N/A	-82.29%	N/A	N/A	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A

Latest GLUC, NBY, LIAN, and ENSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	ENSC Ensysce Biosciences	-$1.02	-$0.79	+$0.23	-$0.79	$0.67 million	$1.37 million
8/8/2025	Q2 2025	GLUC Glucose Health	N/A	-$0.01	N/A	-$0.01	N/A	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENSC Ensysce Biosciences	N/A	N/A	N/A	N/A	N/A
GLUC Glucose Health	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENSC Ensysce Biosciences	N/A	2.10	2.10
GLUC Glucose Health	N/A	N/A	N/A
LIAN LianBio	N/A	10.06	10.06
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENSC Ensysce Biosciences	5.63%
GLUC Glucose Health	N/A
LIAN LianBio	74.85%
NBY NovaBay Pharmaceuticals	23.25%

Insider Ownership

Company	Insider Ownership
ENSC Ensysce Biosciences	7.90%
GLUC Glucose Health	N/A
LIAN LianBio	7.59%
NBY NovaBay Pharmaceuticals	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENSC Ensysce Biosciences	10	2.97 million	2.73 million	Not Optionable
GLUC Glucose Health	147,000	17.41 million	N/A	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable

GLUC, NBY, LIAN, and ENSC Headlines

Recent News About These Companies

NovaBay Pharma Announces Special Cash Dividend

August 26 at 8:08 PM | msn.com

NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

August 26 at 8:08 PM | finance.yahoo.com

Why Is NovaBay Pharmaceuticals Stock (NBY) Up 60% Today?

August 20, 2025 | msn.com

NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

August 19, 2025 | globenewswire.com

NovaBay Pharmaceuticals (NYSE:NBY) Trading Up 2.1% - Time to Buy?

August 16, 2025 | americanbankingnews.com

NBY NovaBay Pharmaceuticals, Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

NovaBay Pharmaceuticals Inc. Stock Grades | NBY | Barron's

May 26, 2025 | barrons.com

NovaBay Pharmaceuticals approves liquidation plan

April 24, 2025 | uk.investing.com

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Poplar Point Capital Partners Acquires 21,654 Shares

April 16, 2025 | insidertrades.com

NovaBay Pharmaceuticals Delays Yearly Report Filing

April 1, 2025 | tipranks.com

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

March 7, 2025 | businesswire.com

NovaBay fails to gain shareholder approval for dissolution

February 5, 2025 | msn.com

NovaBay Pharmaceuticals Inc NBY

February 1, 2025 | morningstar.comM

NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

December 25, 2024 | zacks.com

NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

December 19, 2024 | businesswire.com

NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting

December 9, 2024 | businesswire.com

NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024

November 22, 2024 | businesswire.com

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

November 6, 2024 | businesswire.com

NovaBay Pharmaceuticals To Sell Assets Of Its Avenova Brand - Quick Facts

September 21, 2024 | markets.businessinsider.com

NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.'s Avenova Brand and Business Is Fair to Shareholders

September 20, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUC, NBY, LIAN, and ENSC Company Descriptions

Ensysce Biosciences NASDAQ:ENSC

$2.08 +0.02 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$2.08 +0.00 (+0.19%)

As of 05:32 PM Eastern

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Glucose Health OTCMKTS:GLUC

$0.09 0.00 (0.00%)

As of 08/26/2025 12:45 PM Eastern

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

LianBio NASDAQ:LIAN

$0.05 +0.00 (+0.39%)

As of 08/26/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

NovaBay Pharmaceuticals NYSE:NBY

$1.55 +0.65 (+72.41%)

As of 04:00 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time